Enzomenib clinical trials
Also written DSP-5336.
How each study uses enzomenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enzomenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
2 studies that test it; most in 2022 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Sumitomo Pharma America, Inc. (2) · National Cancer Institute (NCI) (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test enzomenib.
- Jun 2027A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)Phase 1/2 · Sumitomo Pharma America, Inc.
Studies
Open first, then newest update. How each study uses enzomenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate CancerNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07914855Written as Enzomenib
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04988555Written as Enzomenib
- How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood CancersCompletedPhase 1Sumitomo Pharma America, Inc.NCT07444268Written as DSP-5336
Codes
What other systems call enzomenib · ClinicalTrials.gg INT018275
- UNII (FDA) VW83Y2JLZ5ENZOMENIBOne source FDA
- NCI Thesaurus C182007EnzomenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VW83Y2JLZ5 | ENZOMENIB | One source FDA |
| NCI Thesaurus | C182007 | Enzomenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.